Maria Liguori

List of Publications by Year
in descending order

84 papers	4,460 citations	159585 30 h-index	106344 65 g-index
86 all docs	86 docs citations	86 times ranked	6185 citing authors

#	Article	IF	Citations
1	Pharmacoepigenomics in neurodegenerative diseases. , 2021, , 559-581.		0
2	Loss of Neurologic Reserve in Progressive Multiple Sclerosis. Neurology: Clinical Practice, 2021, 11, 271-272.	1.6	0
3	An Investigation of the Role of Common and Rare Variants in a Large Italian Multiplex Family of Multiple Sclerosis Patients. Genes, 2021, 12, 1607.	2.4	4
4	Precision Medicine in Neurodegenerative Diseases: Some Promising Tips Coming from the microRNAsâ€™ World. Cells, 2020, 9, 75.	4.1	10
5	A Pilot Longitudinal Evaluation of MicroRNAs for Monitoring the Cognitive Impairment in Pediatric Multiple Sclerosis. Applied Sciences (Switzerland), 2020, 10, 8274.	2.5	2
6	Listening to the neurological teams for multiple sclerosis: the SMART project. Neurological Sciences, 2020, 41, 2231-2240.	1.9	6
7	Integrated Analysis of microRNA and mRNA Expression Profiles: An Attempt to Disentangle the Complex Interaction Network in Attention Deficit Hyperactivity Disorder. Brain Sciences, 2019, 9, 288.	2.3	22
8	The MicroRNA Centrism in the Orchestration of Neuroinflammation in Neurodegenerative Diseases. Cells, 2019, 8, 1193.	4.1	27
9	Association between miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study. Brain and Behavior, 2019, 9, e01199.	2.2	26
10	Seeking a standardized normalization method for the quantification of microRNA expression. Muscle and Nerve, 2019, 59, E39.	2.2	1
11	A Predictive Model for MicroRNA Expressions in Pediatric Multiple Sclerosis Detection. Lecture Notes in Computer Science, 2019, , 177-188.	1.3	13
12	Counting of peripheral extracellular vesicles in Multiple Sclerosis patients by an improved nanoplasmonic assay and dynamic light scattering. Colloids and Surfaces B: Biointerfaces, 2018, 168, 134-142.	5.0	20
13	Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease. Human Molecular Genetics, 2018, 27, 66-79.	2.9	65
14	Investigating the Role of MicroRNA and Transcription Factor Co-regulatory Networks in Multiple Sclerosis Pathogenesis. International Journal of Molecular Sciences, 2018, 19, 3652.	4.1	40
15	Dysregulation of MicroRNAs and Target Genes Networks in Peripheral Blood of Patients With Sporadic Amyotrophic Lateral Sclerosis. Frontiers in Molecular Neuroscience, 2018, 11, 288.	2.9	93
16	Molecular Characterization of Peripheral Extracellular Vesicles in Clinically Isolated Syndrome: Preliminary Suggestions from a Pilot Study. Medical Sciences (Basel, Switzerland), 2017, 5, 19.	2.9	4
17	Association between MRI structural features and cognitive measures in pediatric multiple sclerosis. , 2017, , .		0
18	Meta-Analysis of Differential Connectivity in Gene Co-Expression Networks in Multiple Sclerosis. International Journal of Molecular Sciences, 2016, 17, 936.	4.1	4

#	Article	IF	Citations
19	Identification of a patient affected by â€œJuvenile-chronicâ€•Tay Sachs disease in South Italy. Neurological Sciences, 2016, 37, 1883-1885.	1.9	3
20	Proteomic Profiling in Multiple Sclerosis Clinical Courses Reveals Potential Biomarkers of Neurodegeneration. PLoS ONE, 2014, 9, e103984.	2.5	30
21	Genomeâ€wide association study in musician's dystonia: A risk variant at the arylsulfatase G locus?. Movement Disorders, 2014, 29, 921-927.	3.9	53
22	Treating epilepsy in Italy between XIX and XX century. Journal of Ethnopharmacology, 2013, 145, 608-613.	4.1	16
23	First mutation in the nuclear localization signal sequence of spastin protein identified in a patient with hereditary spastic paraplegia. European Journal of Neurology, 2013, 20, e22-3.	3.3	2
24	The BDNF Val66Met Polymorphism Has Opposite Effects on Memory Circuits of Multiple Sclerosis Patients and Controls. PLoS ONE, 2013, 8, e61063.	2.5	21
25	Concomitant myotonic dystrophy type 1, CIDPâ€like neuropathy and <scp>H</scp>ashimoto thyroiditis: a causal link?. European Journal of Neurology, 2012, 19, e117-8.	3.3	1
26	CAV3 T78M mutation as polymorphic variant in South Italy. Neuromuscular Disorders, 2012, 22, 669-670.	0.6	8
27	Mobility decline in the elderly relates to lesion accrual in the splenium of the corpus callosum. Age, 2012, 34, 405-414.	3.0	38
28	NOS2A as a candidate gene in Relapsingâ€“Remitting Multiple Sclerosis: A haplotype study using selected subsets of single nucleotide polymorphisms. Journal of the Neurological Sciences, 2011, 304, 75-77.	0.6	2
29	Presenilin enhancerâ€2 gene: Identification of a novel promoter mutation in a patient with earlyâ€onset familial Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 574-578.	0.8	16
30	HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study. Genes and Immunity, 2011, 12, 183-190.	4.1	16
31	One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1125-1131.	1.9	15
32	Identification and Clinical Impact of Multiple Sclerosis Cortical Lesions as Assessed by Routine 3T MR Imaging. American Journal of Neuroradiology, 2011, 32, 515-521.	2.4	77
33	A Putative Alzheimer's Disease Risk Allele in PCK1 Influences Brain Atrophy in Multiple Sclerosis. PLoS ONE, 2010, 5, e14169.	2.5	20
34	HLA B*44. Neurology, 2010, 75, 634-640.	1.1	70
35	Mutation analysis of the SPG4 gene in Italian patients with pure and complicated forms of spastic paraplegia. Journal of the Neurological Sciences, 2010, 288, 96-100.	0.6	27
36	Disease modeling in multiple sclerosis: Assessment and quantification of sources of variability in brain parenchymal fraction measurements. NeuroImage, 2010, 52, 1367-1373.	4.2	25

#	Article	IF	Citations
37	The effects of BDNF Val66Met polymorphism on brain function in controls and patients with multiple sclerosis: An imaging genetic study. Behavioural Brain Research, 2010, 207, 377-386.	2.2	42
38	Neurobiological mechanisms underlying emotional processing in relapsing-remitting multiple sclerosis. Brain, 2009, 132, 3380-3391.	7.6	96
39	CONVENTIONAL MRI AND NOTCH3 GENE SCREENING IN SPORADIC CADASIL. Neurology, 2009, 72, 469-471.	1.1	3
40	Anti-GM1 antibodies are not associated with cerebral atrophy in patients with multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 114-115.	3.0	7
41	A longitudinal observation of Brain-Derived Neurotrophic Factor mRNA levels in patients with Relapsingâ€“Remitting Multiple Sclerosis. Brain Research, 2009, 1256, 123-128.	2.2	28
42	CADASIL: Extended polymorphisms and mutational analysis of the NOTCH3 gene. Journal of Neuroscience Research, 2009, 87, 1162-1167.	2.9	26
43	Brainâ€derived neurotrophic factor and risk for primary adultâ€onset cranialâ€cervical dystonia. European Journal of Neurology, 2009, 16, 949-952.	3.3	17
44	Neurofunctional correlates of personality traits in relapsing-remitting multiple sclerosis: An fMRI study. Brain and Cognition, 2009, 71, 320-327.	1.8	19
45	A phenotypic variation of dominant optic atrophy and deafness (ADOAD) due to a novel OPA1 mutation. Journal of Neurology, 2008, 255, 127-129.	3.6	25
46	Genetic screening for familial amyloid polyneuropathy in patients with idiopathic carpal tunnel syndrome. Journal of the Peripheral Nervous System, 2008, 13, 151-152.	3.1	2
47	Ventro-lateral prefrontal activity during working memory is modulated by MAO A genetic variation. Brain Research, 2008, 1201, 114-121.	2.2	38
48	Preliminary evidences of a NOS2A protective effect from Relapsingâ€“Remitting Multiple Sclerosis. Journal of the Neurological Sciences, 2008, 264, 112-117.	0.6	7
49	OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes. Brain, 2008, 131, 338-351.	7.6	454
50	Impact of catechol-O-methyltransferase Val108/158 Met genotype on hippocampal and prefrontal gray matter volume. NeuroReport, 2008, 19, 405-408.	1.2	66
51	Gene dosage influences the age at onset of SCA2 in a family from southern Italy. Clinical Genetics, 2007, 72, 381-383.	2.0	5
52	Investigating the role of brain-derived neurotrophic factor in relapsing-remitting multiple sclerosis. Genes, Brain and Behavior, 2007, 6, 177-183.	2.2	42
53	Impact of individual cognitive profile on visuo-motor reorganization in relapsingâ€“remitting multiple sclerosis. Brain Research, 2007, 1167, 71-79.	2.2	22
54	The role of VLA4 polymorphisms in multiple sclerosis: An association study. Journal of Neuroimmunology, 2007, 189, 125-128.	2.3	9

#	Article	IF	Citations
55	Corrigendum to â€œLinkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeansâ€•[J. Neuroimmunol. 179 (2006) 108â€“116]. Journal of Neuroimmunology, 2007, 189, 175-176.	2.3	1
56	Fas Antigen and Sporadic Alzheimerâ€™s Disease in Southern Italy: Evaluation of Two Polymorphisms in the TNFRSF6 Gene. Neurochemical Research, 2007, 32, 1445-1449.	3.3	6
57	Adaptive cortical changes and the functional correlates of visuo-motor integration in relapsing-remitting multiple sclerosis. Brain Research Bulletin, 2006, 69, 597-605.	3.0	30
58	Genetic variation in the myeloperoxidase gene and cognitive impairment in Multiple Sclerosis. Journal of Negative Results in BioMedicine, 2006, 5, 3.	1.4	4
59	Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. Journal of Neuroimmunology, 2006, 179, 108-116.	2.3	29
60	Osteopontin gene haplotypes correlate with multiple sclerosis development and progression. Journal of Neuroimmunology, 2005, 163, 172-178.	2.3	66
61	Multiple Sclerosis Severity Score. Neurology, 2005, 64, 1144-1151.	1.1	836
62	A novel mutation (Thr116Ile) in the presenilin 1 gene in a patient with early-onset Alzheimer's disease. European Journal of Neurology, 2004, 11, 521-524.	3.3	20
63	HLAâ€“multiple sclerosis association in Continental Italy and correlation with disease prevalence in Europe. Journal of Neuroimmunology, 2004, 150, 178-185.	2.3	66
64	Association between Synapsin III gene promoter polymorphisms and multiple sclerosis. Journal of Neurology, 2004, 251, 165-170.	3.6	20
65	Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. Journal of Neurology, 2004, 251, 1208-1214.	3.6	142
66	Apolipoprotein E genotype does not influence the progression of multiple sclerosis. Journal of Neurology, 2003, 250, 1094-1098.	3.6	40
67	A whole genome screen for linkage disequilibrium in multiple sclerosis performed in a continental Italian population. Journal of Neuroimmunology, 2003, 143, 97-100.	2.3	17
68	CD45 and multiple sclerosis: the exon 4 C77G polymorphism (additional studies and meta-analysis) and new markers. Journal of Neuroimmunology, 2003, 140, 216-221.	2.3	27
69	Prolactin and prolactin receptor gene polymorphisms in multiple sclerosis and systemic lupus erythematosus. Human Immunology, 2003, 64, 274-284.	2.4	34
70	Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Multiple Sclerosis Journal, 2003, 9, 451-457.	3.0	65
71	Course and prognosis in early-onset MS. Neurology, 2002, 59, 1922-1928.	1.1	305
72	Prospective study of multiple sclerosis with early onset. Multiple Sclerosis Journal, 2002, 8, 115-118.	3.0	134

#	Article	IF	Citations
73	Identification of single nucleotide variations in the coding and regulatory regions of the myelin-associated glycoprotein gene and study of their association with multiple sclerosis. Journal of Neuroimmunology, 2002, 126, 196-204.	2.3	11
74	Age-related disability in multiple sclerosis. Annals of Neurology, 2002, 51, 475-480.	5.3	163
75	Axonal damage in multiple sclerosis plaques: a combined magnetic resonance imaging and 1H-magnetic resonance spectroscopy study. Journal of the Neurological Sciences, 2001, 182, 143-150.	0.6	43
76	Age at onset in multiple sclerosis. Neurological Sciences, 2000, 21, S825-S829.	1.9	65
77	Linkage analysis of multiple sclerosis with candidate region markers in Sardinian and Continental Italian families. European Journal of Human Genetics, 1999, 7, 377-385.	2.8	38
78	Comparison of clinical and demographic features between affected pairs of Italian Multiple Sclerosis multiplex families; relation to tumour necrosis factor genomic polymorphisms. Journal of the Neurological Sciences, 1999, 162, 194-200.	0.6	13
79	Changes of serum sICAM-1 and MMP-9 induced by rIFNÎ²-1b treatment in relapsing-remitting MS. Neurology, 1999, 53, 1402-1402.	1.1	125
80	Multiple sclerosis in childhood: clinical features of 149 cases. Multiple Sclerosis Journal, 1997, 3, 43-46.	3.0	275
81	High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques. Journal of the Neurological Sciences, 1996, 144, 182-190.	0.6	73
82	Prognostic significance of metabolic changes detected by proton magnetic resonance spectroscopy in ischaemic stroke. Journal of Neurology, 1996, 243, 241-247.	3.6	31
83	Proton magnetic resonance spectroscopy in patients with ischemic stroke. Italian Journal of Neurological Sciences, 1994, 15, 413-420.	0.1	6
84	Serum and CSF anti-GM1 antibodies in patients with Guillain-BarrÃ© syndrome and chronic inflammatory demyelinating polyneuropathy. Journal of the Neurological Sciences, 1993, 114, 49-55.	0.6	88